1,380 assets in Cancer

Therapeutic assets addressing Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
68ga-lnc1007 Cancer	Yantai LNC Biotechnology Singapore PTE. LTD.	P1	CC (47)
Amxt1501 Cancer	Aminex Therapeutics, Inc.	P1/2	CC (47)
bi-1808 Cancer	BioInvent International AB	P1/2	CC (47)
ct7439 capsules Cancer	Carrick Therapeutics Limited	P1/2	CC (47)
Inkmune Cancer	Inmune Bio, Inc.	P1/2	CC (47)
js212 for Cancer	Shanghai Junshi Bioscience Co., Ltd.	P1/2	CC (47)
Nadravaleucel Cancer	BOE Technology Group Co., Ltd.	P1/2	CC (47)
Onivyde Cancer	St. Jude Children's Research Hospital	P1/2	CC (47)
Pralatrexate Cancer	Acrotech Biopharma Inc.	P1	CC (47)
rp-001 Cancer	Recurv Pharma Inc	P1/2	CC (47)
Sctb14 Cancer	Sinocelltech Ltd.	P1/2	CC (47)
Sctb41 Cancer	Sinocelltech Ltd.	P1/2	CC (47)
snk02 Cancer	NKGen Biotech, Inc.	P1	CC (47)
TQB2930 for injection Cancer	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	P1/2	CC (47)
tqb3616 Cancer	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	P1/2	CC (47)
Xrd-0394 Cancer	XRad Therapeutics Inc	P1	CC (47)
5-FLUOROURACIL-1.BETA.-D-RIBOFURANOSIDE Cancer	Jiangsu Simcere Pharmaceutical Co., Ltd.	P2	CC (46)
abp1011t Cancer	Shanghai AB PharmaTech Ltd.	P2	CC (46)
Ametinib Cancer	Shanghai Hengrui Pharmaceutical Co., Ltd.	P2	CC (46)
Amivantamab-Vmjw Cancer	Vall d'Hebron Institute of Oncology	P2	CC (46)
Avutometinib Cancer	Verastem, Inc.	P1/2	CC (46)
bat7104 Cancer	Bio-Thera Solutions	P1	CC (46)
bay2927088 Cancer	Bayer	P2	CC (46)
bd0801 Cancer	Jiangsu Simcere Pharmaceutical Co., Ltd.	P2	CC (46)
Botensilimab Cancer	Agenus Inc.	P1	CC (46)
cvl237 tablets Cancer	Convalife (Shanghai) Co., Ltd.	P2	CC (46)
Docetaxel Polymeric Micelles For Cancer	Jiangsu Simcere Pharmaceutical Co., Ltd.	P2	CC (46)
Elraglusib Cancer	Actuate Therapeutics Inc.	P2	CC (46)
Envofolimab Cancer	Jiangsu Simcere Pharmaceutical Co., Ltd.	P2	CC (46)
Fam-Trastuzumab Deruxtecan-Nxki Cancer	Strata Oncology	P2	CC (46)
Futibatinib Cancer	Taiho Oncology, Inc.	P2	CC (46)
her3-dxd Cancer	Daiichi Sankyo	P2	CC (46)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Cdh6(Cadherin 6, K-Cadherin (Foetal Kidney), Cadherin 6 Type 2)], Humanized Monoclonal Antibody Conjugated To Deruxtecan, Comprising A Linker And A Camptothecin Derivative Cancer	Daiichi Sankyo	P2	CC (46)
Inca32459-101 Cancer	Incyte Corporation	P1	CC (46)
Iohexol Cancer	Alison Stopeck	P1	CC (46)
Lazertinib Cancer	Abion Inc	P2	CC (46)
lm-168 Cancer	LaNova Medicines Limited	P2	CC (46)
Lorigerlimab Cancer	MacroGenics	P1	CC (46)
ltc004 Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CC (46)
Personalized Neoantigen Peptide Vaccine Cancer	Seqker Biosciences, Inc.	P1/2	CC (46)
Rosuvastatin Cancer	PMV Pharmaceuticals, Inc	P1	CC (46)
Shr-4602 Cancer	Shanghai Hengrui Pharmaceutical Co., Ltd.	P2	CC (46)
Thymosins Thymalfasin Cancer	Second Affiliated Hospital of Soochow University	P2	CC (46)
Tisotumab Vedotin Cancer	Zai Lab (Shanghai) Co., Ltd.	P1	CC (46)
Vabametkib Cancer	Abion Inc	P2	CC (46)
Veliparib Cancer	National Cancer Institute (NCI)	P1	CC (46)
YH 001 Cancer	Eucure (Beijing) Biopharma Co., Ltd	P1	CC (46)
AK 127 Cancer	Akeso	P1/2	CC (45)
Amt-116 Cancer	Multitude Therapeutics Inc.	P1/2	CC (45)
Amt-253 Cancer	Multitude Therapeutics Inc.	P1/2	CC (45)

Showing 301 to 350 of 1,380 assets

PreviousPage 7 of 28Next